SCHEDULE: UBS Group AG Reports 0% Stake in Reviva Pharmaceuticals

UBS Group AG has filed a Schedule 13G, reporting no beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock as of June 30, 2026.

Summary

• UBS Group AG has filed an amendment to its Schedule 13G filing concerning Reviva Pharmaceuticals Holdings, Inc.
• The filing indicates that UBS Group AG, along with its subsidiaries UBS Financial Services Inc. and UBS Securities LLC, beneficially owns 0 shares of Reviva Pharmaceuticals Holdings, Inc. common stock.
• This represents 0% of the class of securities.
• The filing is an amendment, with the event date requiring the filing being June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it indicates no significant stake by a major financial institution, which could imply a lack of confidence or interest in Reviva Pharmaceuticals Holdings, Inc.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a company's voting stock. A filing reporting 0% ownership by a major financial institution like UBS Group AG suggests a lack of significant investment or a recent divestment.

Stakeholder Impact

• Shareholders: The lack of significant institutional ownership reported by UBS Group AG may be interpreted by the market as a lack of institutional confidence in Reviva Pharmaceuticals Holdings, Inc.

Key Dates

Keywords

UBS Group AG, Reviva Pharmaceuticals Holdings, Schedule 13G, Beneficial Ownership, Securities